MTX as a treatment of OA, by Dr.Conaghan #RNL2023 ⁦@RheumNow⁩ Systemic inflammation might also be a part of OA?! https://t.co/grxMKtRLhj

⚠️Only 12-43% of #PsA patients achieved remission or very low disease activity From systematic review in RWE presented by @DrLauraCoates #RNL2023

Treat to target approach in PsA Systematic rev: 12-43% pts achieved target of very low disease activity or remission Pts and docs agree: remission is primary goal, but Low disease activity is acceptable alternative @DrLauraCoates at #RNL2023 @Rheumnow https://t.co/hA7JDR7Zyh

I love a good graphic. Check out @DrLauraCoates’ review of the impact of MDA in PSAID scores in PsA. #RNL2023 @RheumNow https://t.co/iQYuLQobXL

Treat to target in PSA: What's difference in our outcome scores? DAPSA: includes CRP MDA: includes enthesitis, skin, function Both metrics include Tender/Swollen jt counts, and pt pain/global Presented by @DrLauraCoates at #RNL2023 @RheumNow https://t.co/7i5m70HGiz

Dr. Laura Coates presents - Is remission in PsA attainable? systematic review: 12-43% achieved very low disease activity or remission #RNL2023 @RheumNow https://t.co/flfpzc7B4p

Triamcinolone joint injection, Dr.Conaghan #RNL2023 ⁦@RheumNow⁩ Extended half life steroids injections are better?!: 1- better for sugar control. 2-longer effect. https://t.co/4T8frPJOXG

#RNL2023 @RheumNow @DrLauraCoates: patients & physicians do not agree on what is remission in PsA Patients global scores: largely driven by pain and fatigue, not on joint counts Remission in PsA allows for disease control on Rx- not just drug-free remission, often not sustained https://t.co/Hr2uuWDAfr

Higher Rehospitalization Rates in Younger SLE Patients A Medicare study shows that young adults with SLE exhibit very high 30-day rehospitalization rates (36%) that are significantly higher than older SLE patients and age matched non-SLE patients. https://t.co/17Lbcw8TdC https://t.co/L6CwRCd1aS

• https://bit.ly/3JQNOyV

Can we prevent RA, Kevin Deane #RNL2023 ⁦@RheumNow⁩. https://t.co/EtUEs3MyCN

Upto 30% risk of #RA within 5 yrs if anti-CCP positive #RNL23 https://t.co/E5wun837ud

Conaghan: "Most promising study in OA" at #RNL2023 NGF inhibitor to OA had benefit, but very poorly tolerated - could this be a future tolerated? Can there be sustained response. Conaghan: "In meantime, keep everybody strong" as primary treatment! 💪 @RheumNow https://t.co/eBMEPBG9wn

Stop RA trail: Plaquenil didn’t prevent RA in patient with pre clinical RA. Kevin Deane #RNL2023 ⁦@RheumNow⁩ https://t.co/2Y5am2YEsQ

Conaghan shares unpublished data from PROMOTE study at #RNL2023 Early data shows MTX benefits pain in patients w/ OA, particularly more metabolically active. Looking forward to more data on this - though many many many DMARD trials thus far have been disappointing in OA @RheumNow https://t.co/Ieagp8mq31

30% rule! Risk of RA development in Pre clinical RA patient in the next 3 to 5 years . Kevin Deane #RNL2023 ⁦@RheumNow⁩ https://t.co/J6Polz70im